IMPORTANCE: Cerebral amyloid angiopathy (CAA) is characteristically associated with magnetic resonance imaging (MRI) biomarkers of small vessel brain injury, including strictly lobar cerebral microbleeds, cortical superficial siderosis, centrum semiovale perivascular spaces, and white matter hyperintensities. Although these neuroimaging markers reflect distinct pathophysiologic aspects in CAA, no studies to date have combined these structural imaging features to gauge total brain small vessel disease burden in CAA. OBJECTIVES: To investigate whether a composite score can be developed to capture the total brain MRI burden of small vessel disease in CAA and to explore whether this score contributes independent and complementary information about CAA severity, defined as intracerebral hemorrhage during life or bleeding-related neuropathologic changes. DESIGN, SETTING, AND PARTICIPANTS: This retrospective, cross-sectional study examined a single-center neuropathologic CAA cohort of eligible patients from the Massachusetts General Hospital from January 1, 1997, through December 31, 2012. Data analysis was performed from January 2, 2015, to January 9, 2016. Patients with pathologic evidence of CAA (ie, any presence of CAA from routinely collected brain biopsy specimen, biopsy specimen at hematoma evacuation, or autopsy) and available brain MRI sequences of adequate quality, including T2-weighted, T2*-weighted gradient-recalled echo, and/or susceptibility-weighted imaging and fluid-attenuated inversion recovery sequences, were considered for the study. MAIN OUTCOMES AND MEASURES: Brain MRIs were rated for lobar cerebral microbleeds, cortical superficial siderosis, centrum semiovale perivascular spaces, and white matter hyperintensities. All 4 MRI lesions were incorporated into a prespecified ordinal total small vessel disease score, ranging from 0 to 6 points. Associations with severity of CAA-associated vasculopathic changes (fibrinoid necrosis and concentric splitting of the wall), clinical presentation, number of intracerebral hemorrhages, and other imaging markers not included in the score were explored using logistic and ordinal regression. RESULTS: In total, 105 patients with pathologically defined CAA were included: 52 with autopsies, 22 with brain biopsy specimens, and 31 with pathologic samples from hematoma evacuations. The mean (range) age of the patients was 73 (71-74) years, and 55 (52.4%) were women. In multivariable ordinal regression analysis, severity of CAA-associated vasculopathic changes (odds ratio, 2.40; 95% CI, 1.06-5.45; P = .04) and CAA presentation with symptomatic intracerebral hemorrhage (odds ratio, 2.23; 95% CI, 1.07-4.64; P = .03) were independently associated with the total MRI small vessel disease score. The score was associated with small, acute, diffusion-weighted imaging lesions and posterior white matter hyperintensities in adjusted analyses. CONCLUSIONS AND RELEVANCE: This study provides evidence of concept validity of a total MRI small vessel disease score in CAA. After further validation, this approach can be potentially used in prospective clinical studies.
IMPORTANCE: Cerebral amyloid angiopathy (CAA) is characteristically associated with magnetic resonance imaging (MRI) biomarkers of small vessel brain injury, including strictly lobar cerebral microbleeds, cortical superficial siderosis, centrum semiovale perivascular spaces, and white matter hyperintensities. Although these neuroimaging markers reflect distinct pathophysiologic aspects in CAA, no studies to date have combined these structural imaging features to gauge total brain small vessel disease burden in CAA. OBJECTIVES: To investigate whether a composite score can be developed to capture the total brain MRI burden of small vessel disease in CAA and to explore whether this score contributes independent and complementary information about CAA severity, defined as intracerebral hemorrhage during life or bleeding-related neuropathologic changes. DESIGN, SETTING, AND PARTICIPANTS: This retrospective, cross-sectional study examined a single-center neuropathologic CAA cohort of eligible patients from the Massachusetts General Hospital from January 1, 1997, through December 31, 2012. Data analysis was performed from January 2, 2015, to January 9, 2016. Patients with pathologic evidence of CAA (ie, any presence of CAA from routinely collected brain biopsy specimen, biopsy specimen at hematoma evacuation, or autopsy) and available brain MRI sequences of adequate quality, including T2-weighted, T2*-weighted gradient-recalled echo, and/or susceptibility-weighted imaging and fluid-attenuated inversion recovery sequences, were considered for the study. MAIN OUTCOMES AND MEASURES: Brain MRIs were rated for lobar cerebral microbleeds, cortical superficial siderosis, centrum semiovale perivascular spaces, and white matter hyperintensities. All 4 MRI lesions were incorporated into a prespecified ordinal total small vessel disease score, ranging from 0 to 6 points. Associations with severity of CAA-associated vasculopathic changes (fibrinoid necrosis and concentric splitting of the wall), clinical presentation, number of intracerebral hemorrhages, and other imaging markers not included in the score were explored using logistic and ordinal regression. RESULTS: In total, 105 patients with pathologically defined CAA were included: 52 with autopsies, 22 with brain biopsy specimens, and 31 with pathologic samples from hematoma evacuations. The mean (range) age of the patients was 73 (71-74) years, and 55 (52.4%) were women. In multivariable ordinal regression analysis, severity of CAA-associated vasculopathic changes (odds ratio, 2.40; 95% CI, 1.06-5.45; P = .04) and CAA presentation with symptomatic intracerebral hemorrhage (odds ratio, 2.23; 95% CI, 1.07-4.64; P = .03) were independently associated with the total MRI small vessel disease score. The score was associated with small, acute, diffusion-weighted imaging lesions and posterior white matter hyperintensities in adjusted analyses. CONCLUSIONS AND RELEVANCE: This study provides evidence of concept validity of a total MRI small vessel disease score in CAA. After further validation, this approach can be potentially used in prospective clinical studies.
Authors: Gregory A Dierksen; Maureen E Skehan; Muhammad A Khan; Jed Jeng; R N Kaveer Nandigam; John A Becker; Ashok Kumar; Krista L Neal; Rebecca A Betensky; Matthew P Frosch; Jonathan Rosand; Keith A Johnson; Anand Viswanathan; David H Salat; Steven M Greenberg Journal: Ann Neurol Date: 2010-10 Impact factor: 10.422
Authors: Saima Batool; Martin O'Donnell; Mukul Sharma; Shofiqul Islam; Gilles R Dagenais; Paul Poirier; Scott A Lear; Andreas Wielgosz; Koon Teo; Grant Stotts; Cheryl R McCreary; Richard Frayne; Jane DeJesus; Sumathy Rangarajan; Salim Yusuf; Eric E Smith Journal: Stroke Date: 2014-06-12 Impact factor: 7.914
Authors: Andreas Charidimou; Zane Jaunmuktane; Jean-Claude Baron; Matthew Burnell; Pascale Varlet; Andre Peeters; John Xuereb; Rolf Jäger; Sebastian Brandner; David J Werring Journal: Neurology Date: 2013-11-27 Impact factor: 9.910
Authors: Pim Klarenbeek; Robert J van Oostenbrugge; Rob P W Rouhl; Iris L H Knottnerus; Julie Staals Journal: Stroke Date: 2013-08-27 Impact factor: 7.914
Authors: Susanne J van Veluw; Geert Jan Biessels; Catharina J M Klijn; Annemieke J M Rozemuller Journal: Neurology Date: 2016-02-03 Impact factor: 9.910
Authors: Michael L Alosco; Michael A Sugarman; Lilah M Besser; Yorghos Tripodis; Brett Martin; Joseph N Palmisano; Neil W Kowall; Rhoda Au; Jesse Mez; Charles DeCarli; Thor D Stein; Ann C McKee; Ronald J Killiany; Robert A Stern Journal: J Alzheimers Dis Date: 2018 Impact factor: 4.472
Authors: Gregoire Boulouis; Andreas Charidimou; Michael J Jessel; Li Xiong; Duangnapa Roongpiboonsopit; Panagiotis Fotiadis; Marco Pasi; Alison Ayres; M Emily Merrill; Kristin M Schwab; Jonathan Rosand; M Edip Gurol; Steven M Greenberg; Anand Viswanathan Journal: Neurology Date: 2017-01-27 Impact factor: 9.910
Authors: Gregoire Boulouis; Andreas Charidimou; Marco Pasi; Duangnapa Roongpiboonsopit; Li Xiong; Eitan Auriel; Ellis S van Etten; Sergi Martinez-Ramirez; Alison Ayres; Anastasia Vashkevich; Kristin M Schwab; Jonathan Rosand; Joshua N Goldstein; M Edip Gurol; Steven M Greenberg; Anand Viswanathan Journal: J Neurol Sci Date: 2017-07-09 Impact factor: 3.181
Authors: Susanne J van Veluw; Andreas Charidimou; Andre J van der Kouwe; Arne Lauer; Yael D Reijmer; Isabel Costantino; M Edip Gurol; Geert Jan Biessels; Matthew P Frosch; Anand Viswanathan; Steven M Greenberg Journal: Brain Date: 2016-09-19 Impact factor: 13.501
Authors: Marco Pasi; Gregoire Boulouis; Panagiotis Fotiadis; Eitan Auriel; Andreas Charidimou; Kellen Haley; Alison Ayres; Kristin M Schwab; Joshua N Goldstein; Jonathan Rosand; Anand Viswanathan; Leonardo Pantoni; Steven M Greenberg; M Edip Gurol Journal: Neurology Date: 2017-05-05 Impact factor: 9.910
Authors: Gregoire Boulouis; Ellis S van Etten; Andreas Charidimou; Eitan Auriel; Andrea Morotti; Marco Pasi; Kellen E Haley; H Bart Brouwers; Alison M Ayres; Anastasia Vashkevich; Michael J Jessel; Kristin M Schwab; Anand Viswanathan; Steven M Greenberg; Jonathan Rosand; Joshua N Goldstein; M Edip Gurol Journal: JAMA Neurol Date: 2016-12-01 Impact factor: 18.302